# **Laboratory Case Report**

Student no: 201850379

<u>Using Cardiopulmonary Exercise Testing(CPET) to review cardiopulmonary</u>
<u>and metabolic responses to incremental exercise, and discuss the clinical</u>
<u>implications of the results within Peripheral Artery Disease patients</u>

# Contents

٩Ł	breviation List	4
In	troduction	5
	Aims	6
M	ethodology	7
Se	tting	7
	Equipment list	7
	Rationale for equipment selection and testing methodology	7
	Informed Consent and Risk Assessment	8
	CPET Methodology	9
	Indications for termination of CPET	11
	Criteria for a maximal CPET	11
	Anthropometric Data	11
	Predicted data	12
Re	sults	14
	CPET Performance	14
	Oxygen Consumption	14
	Oxygen Pulse	15
	Ventilatory Anaerobic Threshold	16
	Ventilatory Response	17
	Other noteworthy relationships	19
	Summary of Results – Comparisons to Normative Data	
	scussion	
	Functional Capacity	20

Clinical Exercise Testing, Prescription and Programming	Student no : 201850379
	20
a in Risk Assessment	21
otion and Programming	21
	23
	25
	2.4

#### 700396

## **Abbreviation List**

**CPET**: Cardiopulmonary Exercise Testing

PAD: Peripheral Artery Disease

IC: Intermittent Claudication

**NHS: National Health Services** 

HF: Heart Failure

MI: Myocardial infarction

**COPD**: Chronic Obstructive Pulmonary Disease

**VAT**: Ventilatory Anaerobic Threshold

VT1 and VT2: Ventilatory Threshold 1 and 2

VE: Ventilatory Exchange

VO<sub>2max</sub>: Maximal consumed/utilised oxygen averaged over 30 seconds

**RPE**: Rate of Perceived Exertion

**RER**: Respiratory Exchange Ratio

BACPR: British Association for Cardiovascular Prevention and Rehabilitation

AACVPR: American Association of Cardiovascular and Pulmonary Rehabilitation

NICE: National Institute for Healthcare and Excellence

Cardiopulmonary Exercise Testing(CPET) is a maximal exercise test that provides a global assessment of cardiopulmonary fitness as well as pulmonary and metabolic responses to incremental exercise(Taylor, Nichols, & Ingle, 2015). It combines exercise at maximal intensity with ventilatory gas analyses on a breath-by-breath basis to assess fitness and identify limitations to functional capacity. A CPET therefore has greater diagnostic and clinical utility than a submaximal or self-paced exercise test(Arena et al., 2007; Hodges, Sandercock, Das, & Brodie, 2006).

Peripheral Artery Disease(PAD) is characterized by the abnormal narrowing of the arteries of the limbs due to a build-up of fatty / calcified deposits resulting in decreased oxygen supply to the tissues(Ratchford & Evans, 2014). The disease is characterized by significant exercise intolerance, claudication pain and poor quality of life(Baloch, Abbas, Marone, & Ali, 2018). Physical activity is often symptom limited. PAD patients typically carry a greater risk of cardiovascular mortality and acute coronary events due to their typically advanced age and disease characteristics(Hirsch et al., 2006).

It is therefore important to comprehensively assess their fitness and responses to exercise to arrive at an intervention that can adequately address their impairment. The current evidence is directed towards using CPET data to stratify perioperative risk(Young et al., 2012), but there is a paucity of large datasets that use CPET in PAD cohorts to comment on:

- Disease severity
- Progression
- Baseline for exercise prescription
- > Effectiveness of prescribed pharmaceutical or physical activity interventions

However, a recent study(PREDICT study) in the UK employed CPET in PAD patients to demonstrate how  $VE/VC_{02}$ ,  $VO_{2max}$  and VAT are variables that significantly affect long term patient

Outcomes (Harwood et al., 2018). The study also shows the virtues of using CPET data to inform the creation and implementation of a supervised exercise program within physiological limits of claudication pain. The PREDICT study thus shows that it is possible to implement such protocols for PAD rehabilitation within the NHS and consequently improve the therapist's understanding of the wider risk profile and outcomes involved.

#### Aims

# This report aims to:

- Comment on the functional capacity of the PAD patients in comparison to healthy individuals
- Provide a broad picture regarding the severity of the disease
- > Demonstrate how the CPET results could inform risk assessment in PAD cohorts
- Arrive at comprehensive baseline data which can be used to prescribe safe and effective exercise for symptomatic and functional capacity improvements

## Setting

The testing was conducted at the Physiology Laboratory, University of Hull, UK. The laboratory is large, well lit and well ventilated with ambient temperatures which were comfortable for both the patient and assessor.

## Equipment list

Туре	Model
Cycle Ergometer	General Electric(GE) eBike Ergometer
Gas Analyser	Oxycon Pro
Face mask (for breath gas analysis)	-
3 Litre Calibration Syringe	Hans Rudolf 5530
Sphygmomanometer	Tango Automated Sphygmomanometer
Pulse Oximeter	Nonin Ox Finger Pulse Oximeter
Heart Rate Monitor	Polar FS1 HRM – Monitor and watch
ECG Machine	Marquette Hellige Cardiosmart ECG
ECG Electrodes	Pulse Medical (Gel electrodes)
Weighing Scale	Salter Electronic Weighing Scale
Stadiometer	Holtain Ltd
Inch tape	-
Stethoscope	Littman Stethoscope
Borg Scale of Perceived Exertion (RPE Scale)	Borg 6-20 RPE Scale

<u>Table 1- Testing Equipment</u>

## Rationale for equipment selection and testing methodology

PCPET using cycle ergometry was the preferred testing method. This is because PAD patients find it difficult to tolerate treadmill testing and rarely complete maximal tests.

However, in cycle ergometry, body weight is borne on the saddle rather than on the lower extremity which delays the onset of symptoms thereby improving performance in exercise testing(Oka, Roberta K., Altman, Giacomini, Szuba, & Cooke, 2005; Tuner et al., 2008).

- Cycle ergometry also induces more cardiovascular and metabolic response to exercise testing compared to treadmill testing(Tuner et al., 2008). This could be due to cycle ergometry being better tolerated by PAD patients resulting in longer exercise periods.
- Direct measurement of gas exchange is a reliable, reproduceable method of identifying abnormal haemodynamic responses using the *Oxycon Pro gas analyser*(Hannink et al., 2010) while baseline and exercise ECG help identify cardiac rhythm abnormalities.
- ➤ Ramp protocol of 10 watt per minute increments selected based on Wasserman et al.'s recommendations for populations who might be frail and have chronic disease burdens(Wasserman et al., 2011)

#### Informed Consent and Risk Assessment

Verbal and written informed consent were obtained from the participant. Anthropometric data, medical and treatment history were consequently obtained from an interview with the participant and hospital records. The patient also filled out the 'Pre-exercise medical screening questionnaire' to aid in pre-exercise risk stratification.

Risk assessment was carried out based on:

- Medical history: Ensuring any diagnosis of heart failure, angina, COPD was appropriately managed and if the patient is clinically stable.
- The patient's resting ECG was also scrutinized for any evidence of previous abnormalities such as myocardial infarction, atrial fibrillation, left bundle branch block etc.
- ➤ BACPR and AACVPR guidelines for cardiovascular risk stratification were employed as screening tools(Hirsch et al., 2006)

ACSM criteria for exercise testing: Absolute and relative contraindications were screened for and considered prior to the testing process.

Student no: 201850379

Absolute Contraindications	Relative Contraindications
Recent significant change in resting ECG	Left main coronary artery stenosis
Unstable angina	Moderate stenotic valvular heart disease
Uncontrolled cardiac dysrhythmias	Electrolyte abnormalities/imbalance
Severe aortic stenosis	Severe hypertension; Systolic BP >200mmhg and Diastolic BP>110mmHg at rest
Uncontrolled symptomatic heart failure	Frequent/complex ectopy
Acute pulmonary embolus or pulmonary infarction	Hypertrophic cardiomyopathy
Acute myocarditis or pericarditis	Neuromotor, musculoskeletal or rheumatoid disorders
Suspected or known dissecting aneurysm	Fixed rate pacemaker
Acute systemic infection	Ventricular aneurysm
Thrombophlebitis or intracardiac thrombi	Uncontrolled metabolic disease (Diabetes, thyrotoxicosis etc)
Third degree atrioventricular block without pacemaker	Chronic Infectious disease (HIV)
Recent complicated MI	Mental or physical impairment resulting in inability to exercise adequately
	Advanced/complicated pregnancy

Table 2 – ACSM 2018: Contraindications for exercise testing and participation

#### **CPET Methodology**

The following steps were employed as part of the exercise testing procedure:

- ➤ Short interview to determine the participant's view on current health as well as to identify any patient described limiting factors to exercise performance
- > Patient briefing CPET procedure as well as safety measures explained to the patient
- Informed consent and Pre-exercise Medical Screening Questionnaire (University of Hull Ethics Committee)
- Height and weight were measured. The following baseline vitals were obtained in seated position:
  - Blood pressure
  - Resting heart rate
  - o Breath rate
- Resting ECG obtained in supine position. Modified ECG electrode placement(Mason-Likar) utilised to for both baseline and exercise ECG testing.




Figure 1 - Mason-Likar Placement Figure 2 - Traditional 12-Lead ECG

- Oxycon Pro system calibrated with 3L Syringe. Patient positioned on eBike Ergometer and face mask fitted. Patient asked to remain at rest to check for any vitals or ECG disturbances due to change in body position
- > Patient is instructed to cycle at a cadence of 60-70rpm to maintain consistency throughout the CPET
- 3 minutes of unloaded cycling Considered as the warm up prior to testing
- Ramp protocol at 10W per minute incremental exercise initiated after 3 minutes unloaded cycling. Expected working/exercise test time is 6-12 minutes(Wasserman et al., 2011)
- > 3-minute cool down patient is not required to cycle but vitals as well as gas analyser are monitored to identify any abnormal responses during the recovery phase
- Gas mask removed, patient vitals checked before permitting exit from testing area

#### Indications for exercise termination

Chest pain suggestive of ischaemia

Ischaemic ECG changes

Complex ectopy

Second- or third-degree heart block

Fall in systolic pressure >20 mm Hg from the highest value during the test

Hypertension (>250 mm Hg systolic; >120 mm Hg diastolic)

Severe desaturation: Spo $_2 \le 80\%$  when accompanied by symptoms and signs of severe hypoxaemia

Sudden pallor

Loss of coordination

Dizziness or faintness

Signs of respiratory failure

Mental confusion

Adapted from ATS/ACCP Statement on Cardiopulmonary Exercise Testing.

Figure 3 – Termination criteria(Hirsch et al., 2006)

#### Criteria for a maximal CPET

Achieving one or more of the given criteria (Wasserman et al., 2011) constitutes the completion of a maximal CPET :

- > RER >1.15
- Achieved maximal HR during the test within 15% of their age predicted HR<sub>max</sub>
- ➤ RPE >17
- VO2 plateau over 30 seconds

#### Anthropometric Data

Patient	Age	Measured Height (cm)	Measured Weight (kg)	вмі	Predicted HR <sub>max</sub>	Resting Heart Rate
PAD 1	71	183	88.2	26.33	149 bpm	66 bpm

<u>Table 3 – PAD Patient Anthropometric data</u>

700396 Clinical Exercise Testing, Prescription and Programming Student no : 201850379 Patient is Caucasian male, classified as overweight due to BMI over normative values for his age, gender and ethnicity. Age predicted  $HR_{max}$  was calculated based on the Karvonen method (220-age)(Fox, Naughton, & Haskell, 1971).

# Predicted data

Predicted data calculated using Wasserman-Hansen equations (Wasserman et al., 2011) under the assumption that the participant is sedentary owing to long standing PAD. The patient is male and CPET was performed on a cycle ergometer.

Age	71
Predicted Weight	83.87kg
Age predicted HR <sub>max</sub> (220-age)	149
Predicted VO <sub>2max</sub>	2064.86 ml/min (or 24.61 ml/kg/min)
Normative VAT threshold	49-63% of VO2
Predicted Oxygen Pulse	13.86 ml/beat

<u>Table 4 – CPET Predicted Data for PAD Patient 1</u>

Wasserman/	Sedentary male	Sedentary Female
Hansen	Step 1: Calculate	Step 1: Calculate
equations <sup>a</sup>	Cycle factor = $50.72 - 0.372(age)$	Cycle factor = $22.78 - 0.17$ (age)
	Predicted weight = $0.79$ (height) $-60.7$	Predicted weight = 0.65 (height) - 42.8
	Step 2: Classify weight	Step 2: Classify weight
	Measured weight = predicted weight	Measured weight = predicted weight
	Step 3: Select equation	Step 3: Select equation
	Measured weight < Predicted weight	Measured weight < Predicted weight
	Peak $V_{O_2}$ (mL • min <sup>-1</sup> ) = [(Predicted weight + Actual	Peak $V_{O_2}$ (mL • min <sup>-1</sup> ) = [(Predicted weight + Actual weight)
	weight)/2] $\times$ cycle factor	+86)/2] × cycle factor
	Measured weight = Predicted weight	Measured weight = Predicted weight
	Peak $V_{O_2}$ (mL • min <sup>-1</sup> ) = Measured weight × cycle factor	Peak $V_{O_2}$ (mL • min <sup>-1</sup> ) = (Measured weight + 43) × cycle
	Measured weight > Predicted weight	factor
	Peak $V_{O_2}$ (mL • min <sup>-1</sup> ) = (Predicted weight × cycle	Measured weight > Predicted weight
	factor) $+ 6 \times$ (Measured weight – predicted weight)	Peak $V_{O_2}$ (mL • min <sup>-1</sup> ) = (Predicted weight + 43) × cycle
	Step 4: Mode of exercise consideration	factor + 6 × (Measured weight - predicted weight)
	If treadmill used for test	Step 4: Mode of exercise consideration
	Multiply predicted $V_{O_2}$ from step 3 $\times$ 1.11	If treadmill used for test
	26.3	Multiply predicted $V_{\rm O}$ , from step 3 $\times$ 1.11

Figure 4 - Wasserman-Hansen equations for peak VO2

The CPET data was collected and the relationship between the variables were represented

graphically based on Wasserman's principles of exercise testing. The data analysed will be 15 second data as it provides better data to plot graphically than 5 second data. 5 second data leads to vast number of closely located points which creates a lot of noise/discordance within the graphs. Wasserman describes a 9-panel plot.

Graph	Relationship (Y on X nomenclature)
Plot 1	VO2, VC <sub>02</sub> , Workload on Time
Plot 2	Heart rate and Oxygen Pulse on time
Plot 3	Heart rate, VC <sub>02</sub> on VO2
Plot 4	VE/VO2 and VE/ VC <sub>O2</sub> on time
Plot 5	Not plotted due to insufficient data
Plot 6	V VC <sub>02</sub> on VE
Plot 7	Not plotted due to insufficient data
Plot 8	RER on time
Plot 9 Not plotted due to insufficient data	

<u>Table 5 – CPET 9-panel plots</u>

#### **CPET Performance**

The patient has completed a maximal CPET. This is evidenced by the fact that he has achieved nearly all the criteria for a maximal test where he has :

Student no: 201850379

- > Achieved RER >1.15 indicating maximal effort
- Plateau in oxygen consumption clearly visible in plot 1
- Achieved 100% of his predicted HR<sub>max</sub>

Peak workload achieved was 126 watts and incremental exercise time was 11 minutes and 15 seconds.

RPE data was unavailable for this data set. Normal heart rate response in recovery is observed with >20 beats

per minute decrease observed across the first minute and > 40 beats across the second minute of recovery.

#### Oxygen Consumption




Figure 5 – Oxygen uptake and expired carbon dioxide throughout the test

Panel 1 shows the maximal oxygen intake achieved by the patient evidenced by a plateau in oxygen consumption in response to increasing workloads. In clinical populations, this plateau may not be evident in all patients who undergo a CPET(Coeckelberghs, Buys, Goetschalckx, Cornelissen, & Vanhees, 2016). So, the point highest value of oxygen consumption is recorded. This is termed as VO2 peak. Therefore, VO2 peak is a much more appropriate measure for oxygen consumption than VO<sub>2max</sub> in clinical populations.

As per Wasserman-Hansen equations, the patient was predicted to achieve a maximal oxygen uptake of 2046.83ml/min (displayed on the graph by a dashed line). However, the patient only achieved 1550ml/min as his VO2 peak. This patient did achieve the desired plateau resulting in his VO2max of 1535ml/min. He maintains this plateau for approximately 60 seconds.

#### Oxygen Pulse




Figure 6 – Oxygen consumed per heart beat

This panel displays the volume of oxygen consumed per heart beat(Oxygen pulse) along with heart rate against time. The patient has achieved a peak oxygen pulse of 11.48ml/beat. However, the

## Ventilatory Anaerobic Threshold




Figure 7 – Expired carbon dioxide and heart rate relationship against oxygen uptake

Plot 3 is used to identify the patient's VAT from the  $VC_{02}/VO_2$  relationship. VAT is identified and expressed as a percentage of maximal oxygen uptake. The patient's VAT is identified to occur at 0.96 l/min  $VO_2$  and 0.82 l/min  $VC_{02}$ at a heart rate of 96bpm. Therefore, he has reached his VAT at 62% of  $VO_{2max}$ . This was achieved at a workload of 58 watts.

In healthy individuals, VAT is expected to lie between 48%-63% of VO<sub>2max</sub> (Wasserman et al., 2011). Within this context, the patient meets normative criteria.




Figure 8 – Expired carbon dioxide and inspired oxygen per ventilatory exchange

Plot 4 displays the relationship between VE/CO<sub>2</sub> and VE/ VO<sub>2</sub>throughout the testing period. It helps identify the point where the inspired oxygen is insufficient to buffer the carbon dioxide and lactate build up. There is a clear shift or inflection in the graph noted at 14:15 mins where VE/ VO<sub>2</sub> increases rapidly compared to VE/ VCO<sub>2</sub>. This point is termed at the ventilatory compensation point(Nichols, Taylor, & Ingle, 2015).




Figure 9 – Ventilatory Exchange and Carbon dioxide relationship

Plot 6 of the CPET gives further information about the ventilatory responses to incremental exercise. This plot is used to find out if the respiratory compensation point has been met. The RCP is the nadir value before the relationship becomes non-linear. Another important factor is the slope of this relationship, which helps identify disorders in the pulmonary system.

The slope is calculated before the RCP, i.e. where the relationship remains linear. For this patient, the slope was calculated to be 30.25 which shows a normal relationship (Poggio, Arazi, Giorgi, & Miriuka, 2010).




Figure 10 – Oxygen pulse and Workload relationship

A normal oxygen pulse-workload relationship is seen to be a steep linear increase, directly correlated to the increase in workload. However, in this patient we see a muted response. The slope is observed to be 8.1. For his age, the slope of this relationship should be closer to  $10 \pm 1$ .

#### Summary of Results – Comparisons to Normative Data

The following table summarizes the results of participant's CPET performance and compares his data to the normative values for a healthy male of his age.

<u>P</u> arameter	Measured Data	Normative Data	
Peak VO₂	1550ml/min or 19ml/min/kg	23 ± 5.4 (Barron et al., 2015)	
VAT	62% of VO₂ peak	48-63% of VO2 peak	
		(Wasserman et al., 2011)	
Oxygen Pulse	11.48ml/beat	19.3 ± 3.5 (Albouaini, Egred,	
		Alahmar, & Wright, 2007)	
Peak RER (Exercise)	1.16	1.11 ± 0.08(Wasserman et al.,	
		2011)	
VE/ VCO₂ Slope	30.25	19.12-30.66(Koch et al., 2009)	
Peak Work Rate	126 Watts	188 ± 43 Watts (Albouaini et	
		al., 2007; Meyer et a <mark>.</mark> , 1994)	

Table 6 – Summary of results

# Functional Capacity

As evidenced by the subnormal  $VO_{2max}$  and the dulled relationship between oxygen pulse and workload, the patient has impaired functional capacity.  $VO_{2max}$  is a good prognostic indicator within cardiovascular disease(Ingle et al., 2011). The patient's  $VO_{2max}$  falls within the lower bounds of normative data indicating some underlying pathology of the cardiovascular system.

Student no: 201850379

The oxygen pulse-workload slope is a good indicator of skeletal muscle function (Harwood et al., 2018). The patient shows signs of deconditioning which is evidenced by the muted response observed in figure 10. The combination of the above factors show how PAD and IC has affected the exercise capacity of the patient and displays the virtues of using a CPET to identify this when simpler methods such as maximal walking distance via a treadmill test would be unable to identify these fine details (Bronas, 2007).

#### **Disease Severity**

VO<sub>2max</sub>, Oxygen pulse-workload, VE/ VCO<sub>2</sub>slope and VAT obtained from the CPET help comment on disease severity. The VO<sub>2max</sub> and oxygen pulse measured are lower than the normative data. But VAT and VE/ VCO<sub>2</sub>slope are more sensitive prognostic markers for cardiovascular disease than VO<sub>2max</sub> (Ingle et al., 2011; Poggio et al., 2010). VAT is an important measure since all work below this threshold is equivalent to the aerobic capacity required to perform activities of daily living. The measured values for these parameters fall within the normative limits for age and sex. However, it is important to note that the modality of CPET (treadmill vs cycle ergometer) can impact the VO<sub>2max</sub> and the VAT response(Balady et al., 2010). Typically, these parameters are identified at lower thresholds in treadmill testing.

Therefore, the above data leads to the conclusion that the disease burden remains but there is no major impact on functional capacity and general health as initially hypothesized. It also lends

Clinical Exercise Testing, Prescription and Programming Student no: 201850379 weight to the argument that in the case of this patient, the functional capacity is affected by claudication pain than by the disease severity itself(Oka, R. K., Altman, Giacomini, Szuba, & Cooke, 2005).

#### Role of CPET Data in Risk Assessment

PAD patients carry a higher risk of cardiovascular mortality. However, up to 30% of all PAD patients have normal coronaries(Ratchford & Evans, 2014). Therefore, risk stratification using standardized tools may not be the most accurate. The addition of a CPET to standardized tests of cardiopulmonary function could improve overall patient outcomes by accurately estimating cardiovascular disease risk(Young et al., 2012).

As explained earlier, the results from the various relationships in the 9-panel Wasserman plot help establish a global picture of the disease with focus on the functional capacity as well as metabolic and pulmonary responses. With the emergence of VO<sub>2max</sub>, VE/ VCO<sub>2</sub> slope and OUES as significant prognostic tools(Harwood et al., 2018; Ingle et al., 2011; Poggio et al., 2010), a statistically significant change in these parameters can indicate a change in the disease profile and consequently better risk stratify the patient.

#### **Exercise Prescription and Programming**

CPET data can be extremely helpful in planning an exercise intervention or assessing the efficacy of a prescribed intervention in patients who have a chronic disease burden. Exercise interventions can be prescribed on the basis of :

➤ VAT – Exercise training at VAT zone results in an increase in VO₂ at VAT by anywhere between 10 and 25% in sedentary or frail individuals(Balady et al., 2010). It is also noted that training between VT1 and VT2 results in a series of metabolic changes in the muscles.Consequently, regular exercise results in the elevation of the VAT and improved peripheral utilisation of oxygen and buffering of lactate resulting in improved functional capacity.

VO<sub>2max</sub> (Gold standard) – While VO<sub>2max</sub> does not account for individual differences in metabolic stress, it is a much more effective form of exercise prescription at low to moderate intensity when compared to percentage heart rate reserve(Mann, Lamberts, & Lambert, 2013). Another study showed that exercise prescribed at 75% of VO<sub>2max</sub> resulted in progressive increase in thresholds for blood lactate levels in heterogenous populations(Scharhag-Rosenberger, Meyer, Gässler, Faude, & Kindermann, 2010).

These methods of exercise prescription give superior results in terms of the participant's physiological responses to exercise. It subsequently helps accurately monitor the body's adaptations to exercise training by quantifying the VO<sub>2max</sub> and VAT which are more sensitive to change than heart rate adaptations to exercise (Cortes et al., 1997; Mann et al., 2013).

With respect to PAD, the current guidelines in the UK recommend at least 30 minutes of walking daily(Hirsch et al., 2006). The patient must walk at a speed that induces claudication pain. However, this may not prove to be effective due to lack of supervision to ensure that patients follow the guideline.

A supervised exercise program is therefore more beneficial (Harwood et al., 2018) to the patients. While there is paucity of evidence exploring the utility of  $VO_{2max}$  and VAT to prescribe exercise within a PAD cohort, it is safe to assume that the available benefits from doing so will greatly improve the functional capacity of the patient and address symptoms of claudication.

## Conclusion

CPET is being increasingly implemented within a clinical setting. The detailed assessment of the cardiopulmonary and metabolic physiology can inform clinical decision making within the context of pharmacological and exercise management. The modes of exercise prescription can be better modulated to suit the patient using CPET data and it would be foolish to discount the odds of superior results compared to the traditional methods of exercise prescription. Patients with chronic diseases can only benefit from an exercise rehabilitation point of view thereby displaying the value of CPET.

1) Albouaini, K., Egred, M., Alahmar, A., & Wright, D. J. (2007). Cardiopulmonary exercise testing and its application. *Postgraduate Medical Journal*, 83(985), 675-682. Retrieved from <a href="http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105859308&site=ehost-live">http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105859308&site=ehost-live</a>

Student no: 201850379

- 2) Arena, R., Myers, J., Williams, M. A., Gulati, M., Kligfield, P., Balady, G. J., Fletcher, G. (2007).

  Assessment of functional capacity in clinical and research settings: A scientific statement from the american heart association committee on exercise, rehabilitation, and prevention of the council on clinical cardiology and the council on cardiovascular nursing. *Circulation*, *116*(3), 329-343.
- 3) Balady, G. J., Arena, R., Sietsema, K., Myers, J., Coke, L., Fletcher, G. F., Coke, L. (2010). Clinician's guide to cardiopulmonary exercise testing in adults: A scientific statement from the american heart association. *Circulation*, 122(2), 191-225. doi:10.1161/CIR.0b013e3181e52e69
- 4) Baloch, Z. Q., Abbas, S. A., Marone, L., & Ali, A. (2018). Cardiopulmonary exercise testing limitation in peripheral arterial disease. *Annals of Vascular Surgery, 52*, 108-115. doi:10.1016/j.avsg.2018.03.014
- 5) Barron, A. J., Dhutia, N. M., Gläser, S., Koch, B., Ewert, R., Obst, A., Wensel, R. (2015).
  Physiology of oxygen uptake kinetics: Insights from incremental cardiopulmonary exercise
  testing in the study of health in pomerania. *IJC Metabolic & Endocrine*, 7, 3-9. Retrieved from
  <a href="http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=26339572&site=ehost-live">http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=26339572&site=ehost-live</a>
- 6) Bronas, U. G. (2007). Comparison of the effect of upper body ergometer aerobic training vs.

  treadmill training on walking distance in patients with claudication: Influence of central

  cardiorespiratory improvement: A randomized controlled study . (109849263). Retrieved from

- 7) Coeckelberghs, E., Buys, R., Goetschalckx, K., Cornelissen, V., & Vanhees, L. (2016). Prognostic value of the oxygen uptake efficiency slope and other exercise variables in patients with coronary artery disease. *European Journal of Preventive Cardiology*, *23*(3), 237-244. doi:10.1177/2047487315569410
- 8) Cortes, C. W., Mehal, W., Wang, R. Y., Poznek, E. J., Bradley, K. D., Goetz, J. M., Downie, R. W. (1997). Reliability of exercise cardiopulmonary responses in older persons with moderate-to-heavy chronic disease burdens. *Measurement in Physical Education & Exercise Science*, 1(3), 153. doi:10.1207/s15327841mpee0103\_1
- 9) Fox, S. M., 3, Naughton, J. P., & Haskell, W. L. (1971). Physical activity and the prevention of coronary heart disease. *Annals of Clinical Research*, *3*(6), 404-432. Retrieved from <a href="http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=4945367&site=ehost-live">http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=4945367&site=ehost-live</a>
- 10) Hannink, J., Lahaije, A., Verberkt, C., Dekhuijzen, R., van Helvoort, H., & Heijdra, Y. (2010).
  Validity of oxycon mobile in measuring inspiratory capacity in healthy subjects. *Clinical Physiology & Functional Imaging*, 30(3), 206-209. Retrieved from
  <a href="http://search.ebscohost.com/login.aspx?direct=true&db=s3h&AN=48857496&site=ehost-live">http://search.ebscohost.com/login.aspx?direct=true&db=s3h&AN=48857496&site=ehost-live</a>
- 11) Harwood, A. E., Totty, J. P., Pymer, S., Huang, C., Hitchman, L., Carradice, D., Chetter, I. C. (2018). Cardiovascular and musculoskeletal response to supervised exercise in patients with intermittent claudication. *Journal of Vascular Surgery*, doi:10.1016/j.jvs.2018.10.065
- 12) Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Riegel, B. (2006). ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the american association for vascular surgery/society for vascular surgery, society

for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-society consensus; and Vascular Disease Foundation. *Circulation*, 113(11), e654.

- 13) Hodges, L. D., Sandercock, G. R. H., Das, S. K., & Brodie, D. A. (2006). Cardiac pumping capability in patients with peripheral vascular disease. *Clinical Physiology & Functional Imaging*, 26(3), 185-190.
- 14) Ingle, L., Sloan, R., Carroll, S., Goode, K., Cleland, J. G., & Clark, A. L. (2011). Prognostic significance of different measures of the ventilation-carbon dioxide relation in patients with suspected heart failure. *European Journal of Heart Failure*, *13*(5), 537-542. doi:10.1093/eurjhf/hfq238
- 15) Koch, B., Schäper, C., Ittermann, T., Spielhagen, T., Dörr, M., Völzke, H., Gläser, S. (2009).

  Reference values for cardiopulmonary exercise testing in healthy volunteers: The SHIP study. *The European Respiratory Journal*, 33(2), 389-397. doi:10.1183/09031936.00074208
- 16) Mann, T., Lamberts, R. P., & Lambert, M. I. (2013). Methods of prescribing relative exercise intensity: Physiological and practical considerations. *Sports Medicine (Auckland, N.Z.), 43*(7), 613-625. doi:10.1007/s40279-013-0045-x
- 17) Meyer, K., Hajric, R., Samek, L., Baier, M., Lauber, P., Betz, P., & Roskamm, H. (1994).

  Cardiopulmonary exercise capacity in healthy normals of different age. *Cardiology*, *85*(5), 341-351.

281-289. doi:10.12968/hmed.2015.76.5.281

- 19) Oka, R. K., Altman, M., Giacomini, J. C., Szuba, A., & Cooke, J. P. (2005). Abnormal cardiovascular response to exercise in patients with peripheral arterial disease: Implications for management. *Journal of Vascular Nursing*, 23(4), 130-138. Retrieved from <a href="http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106396293&site=ehost-live">http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106396293&site=ehost-live</a>
- 20) Oka, R. K., Altman, M., Giacomini, J. C., Szuba, A., & Cooke, J. P. (2005). Abnormal cardiovascular response to exercise in patients with peripheral arterial disease: Implications for management. *Journal of Vascular Nursing: Official Publication of the Society for Peripheral Vascular Nursing*, 23(4), 130-136. Retrieved from <a href="http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16326331&site=ehost-live">http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16326331&site=ehost-live</a>
- 21) Poggio, R., Arazi, H. C., Giorgi, M., & Miriuka, S. G. (2010). Prediction of severe cardiovascular events by VE/VCO2 slope versus peak VO2 in systolic heart failure: A meta-analysis of the published literature. *American Heart Journal*, *160*(6), 1004-1014. doi:10.1016/j.ahj.2010.08.037
- 22) Ratchford, E. V., & Evans, N. S. (2014). Vascular disease patient information page: Peripheral artery disease. *Vascular Medicine*, *19*(3), 218-220. doi:10.1177/1358863X14534803
- 23) Scharhag-Rosenberger, F., Meyer, T., Gässler, N., Faude, O., & Kindermann, W. (2010).
  Exercise at given percentages of VO2max: Heterogeneous metabolic responses between individuals. *Journal of Science and Medicine in Sport, 13*(1), 74-79.
  doi:10.1016/j.jsams.2008.12.626

- 25) Tuner, S. L., Easton, C., Wilson, J., Byrne, D. S., Rogers, P., Kilduff, L. P., Pitsiladis, Y. P. (2008).
  Cardiopulmonary responses to treadmill and cycle ergometry exercise in patients with
  peripheral vascular disease. *Journal of Vascular Surgery*, 47(1), 123-130.
  doi:10.1016/j.jvs.2007.09.001
- 26) Wasserman, K., Hansen, J., Sue, D., Sietsema, K., Whipp, J., B, Stringer, W., W, Sun, X. G. (2011). *Principles of exercise testing and interpretation :Including pathophysiology and clinical applications* (Fifth ed.). Philadelphia: Lippincott Williams and Wilkins.
- 27) Young, E. L., Karthikesalingam, A., Huddart, S., Pearse, R. M., Hinchliffe, R. J., Loftus, I. M., Holt, P. (2012b). A systematic review of the role of cardiopulmonary exercise testing in vascular surgery. *European Journal of Vascular and Endovascular Surgery*, 44(1), 64-71.